- Home
- CRSP vs VRN Comparison
CRSP vs VRN Comparison
Compare CRSP & VRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- VRN
- Stock Information
- Founded
- CRSP 2013
- VRN 1994
- Country
- CRSP Switzerland
- VRN Canada
- Employees
- CRSP N/A
- VRN N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- VRN Oil & Gas Production
- Sector
- CRSP Health Care
- VRN Energy
- Exchange
- CRSP Nasdaq
- VRN Nasdaq
- Market Cap
- CRSP 4.3B
- VRN 4.3B
- IPO Year
- CRSP 2016
- VRN N/A
- Fundamental
- Price
- CRSP $43.65
- VRN $4.62
- Analyst Decision
- CRSP Buy
- VRN Strong Buy
- Analyst Count
- CRSP 18
- VRN 2
- Target Price
- CRSP $76.60
- VRN $11.50
- AVG Volume (30 Days)
- CRSP 1.8M
- VRN 6.8M
- Earning Date
- CRSP 11-05-2024
- VRN 10-31-2024
- Dividend Yield
- CRSP N/A
- VRN 7.10%
- EPS Growth
- CRSP N/A
- VRN N/A
- EPS
- CRSP N/A
- VRN 1.31
- Revenue
- CRSP $202,829,000.00
- VRN $2,851,178,799.00
- Revenue This Year
- CRSP N/A
- VRN $31.35
- Revenue Next Year
- CRSP $758.18
- VRN N/A
- P/E Ratio
- CRSP N/A
- VRN $3.55
- Revenue Growth
- CRSP 19.31
- VRN 23.15
- 52 Week Low
- CRSP $42.86
- VRN $4.52
- 52 Week High
- CRSP $91.10
- VRN $9.28
- Technical
- Relative Strength Index (RSI)
- CRSP 39.11
- VRN 27.33
- Support Level
- CRSP $43.40
- VRN $4.51
- Resistance Level
- CRSP $53.97
- VRN $5.05
- Average True Range (ATR)
- CRSP 2.37
- VRN 0.13
- MACD
- CRSP -0.78
- VRN -0.03
- Stochastic Oscillator
- CRSP 9.53
- VRN 14.46
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About VRN Veren Inc. Common shares
Veren Inc is an oil producer company. It is engaged in acquiring, developing, and holding interests in petroleum assets operations across western Canada.